Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma. Issue 6 (June 2019)

• Record Type: Journal Article
• Authors: Ye, Minfeng; Lv, Jieqing; Xu, Guangen; Wang, Wei; Jing, Yuanming; Sun, Aijing; Lu, Zengxin; Wu, Xue; Liu, Yichuan; Shao, Yang W.; Liu, Fang; Tao, Feng
• Is Part Of: Journal of international medical research. Volume 47:Issue 6(2019)
• Page Start: 2768
• Page End: 2777
• Publication Date: 2019-06
• Subjects: Gallbladder carcinoma -- HER2 amplification -- dual-targeted therapy -- trastuzumab -- lapatinib -- tumor; Medicine -- Periodicals; Pharmacology -- Periodicals; 610.5
• DOI: 10.1177/0300060519847796
• Languages: English
• ISSNs: 0300-0605

Abstract

Gallbladder carcinoma (GBC) is a rare and highly aggressive tumor. Early diagnosis is challenging, which results in a poor prognosis using systemic therapy. Recent studies have identified a subset of GBC patients with HER2 gene (ERBB2) amplification that could benefit from HER2-targeted therapy. Here, we report one patient with recurrent metachronous GBC with metastasis, who received the combination of trastuzumab and lapatinib. This approach achieved a partial response for both the brain and the lung metastases. This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib, it can effectively target brain metastasis.